US Anti-Obesity Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route of Administration, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$6.34 BnPlaceholder estimate
Estimate 2025$7.98 Bn44.3% of the global market
Projected 2034$63.46 Bn 694.8%Adds $55.47 Bn over 9 forecast years
CAGR 2025–203425.9%Faster than 96% of 180 Pharmaceuticals markets here
58 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Anti-Obesity Drugs Market Analysis Executive Summary
Anti-obesity drugs help people with obesity lose weight and keep it off by reducing appetite, increasing fullness or blocking fat absorption.
Key segments of the anti-Obesity Drugs market include drug class (GLP-1 Agonists, Dual and Triple Agonists and Lipase Inhibitors) and route of administration (Injectable and Oral).
US Anti-Obesity Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Anti-Obesity Drugs Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the anti-Obesity Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the anti-Obesity Drugs market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the anti-Obesity Drugs market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Anti-Obesity Drugs Market in US
The anti-Obesity Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Anti-Obesity Drugs Market in US
Anti-Obesity Drugs in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 58 studies on Anti-Obesity Drugs that are recruiting, active or about to start in the US.[3] Obesity (adults): 41.0% of adults in 2024, the latest WHO figure for the US.[4]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for anti-Obesity Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Route of Administration
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novo Nordisk
7.2 Eli Lilly and Company
7.3 Boehringer Ingelheim
7.4 Amgen
7.5 Currax Pharmaceuticals
7.6 Rhythm Pharmaceuticals
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The anti-Obesity Drugs market can be segmented based on various criteria, including drug class, route of administration and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Anti-Obesity Drugs right now, from free public sources.
How big is the Anti-Obesity Drugs market in the US?
Placeholder estimate: about $7.98 Bn in 2025, rising to about $63.46 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Anti-Obesity Drugs market in the US growing?
Placeholder estimate: about 25.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Anti-Obesity Drugs market report cover?
The report splits the market by drug class (GLP-1 Agonists, Dual and Triple Agonists, Lipase Inhibitors, Combination Drugs), route of administration (Injectable, Oral) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Anti-Obesity Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Currax Pharmaceuticals and Rhythm Pharmaceuticals.
What is driving the Anti-Obesity Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the anti-Obesity Drugs market.
Who regulates Anti-Obesity Drugs in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Anti-Obesity Drugs are running in the US?
58 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Obesity (adults): 41.0% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.